¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÉÇ÷°üÁßÀçÇÐȸ The 2nd K-SCI Symposium : 2019-04-13

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÉÇ÷°üÁßÀçÇÐȸ The 2nd K-SCI Symposium : 2019-04-13
±³À°ÀÏÀÚ : 2019-04-13
±³À°Àå¼Ò : ¿¬¼¼´ëÇб³ ¹é¾ç´©¸® ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : The 2nd K-SCI Symposium
ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
´ã´çÀÚ : Á¤ÀºÇý
¿¬¶ôó : 02-582-8212  
À̸ÞÀÏ : grace@kscvi.org      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 -´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¤È¸¿ø ¹«·á * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 09:00~09:40 TAVR Case  ÃÖ½ÂÇõ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 09:40~09:52 Balloon Expandable vs. Self-expandable Valve: Considerations before Procedure  ÀÌÁßÈñ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 09:52~10:04 TAVR for Patients with Inappropriate Access  °í¿µ±¹(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 10:04~10:16 Complications after TAVR: How Can We Detect & Treat?  ¹Ú´ö¿ì(¿ï»êÀÇ´ë) 
Åä·Ð 04-13 ±×·£µåº¼·ë 10:16~10:30 Discussion  () 
È޽Ġ04-13  10:30~10:50 Coffee Break  () 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 10:50~11:30 PMV or Mitral valve case  ÇÑÁÖ¿ë(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 11:30~11:42 PMV: Step by Step  ±èÁß¼±(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 11:42~11:54 Paravalular Leakage  °íÀ±¼®(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 11:54~12:06 Mitral Clip: Clinical Evidence and Technique  ±èÁØÈ«(ºÎ»êÀÇ´ë) 
Åä·Ð 04-13 ±×·£µåº¼·ë 12:06~12:20 Discussion  () 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 12:20~12:50 Edwards SAPIEN 3 : Insurmountable Execellency of Procedural Optimization and Long Term Durability  Àå±âÀ°(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 12:50~13:20 Recent Updates From Evolut R/PRO Technology and Outcomes  È«¸í±â(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 13:20~14:00 LAAO Case  ±èÁß¼±(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 14:00~14:12 Optimal Pre- and Post-procedural Anticoagulation and Antiplatelet Strategy  ¾öÀç¼±(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 14:12~14:24 The Role of LAAO in NOAC Era  ÀÌ¿ÀÇö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 14:24~14:36 LAA Occlusion with ICE  ½Å½Â¿ë(Áß¾ÓÀÇ´ë) 
Åä·Ð 04-13 ±×·£µåº¼·ë 14:36~14:50 Discussion  () 
È޽Ġ04-13  14:50~15:10 Coffee Break  () 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 15:10~15:50 ASD or PFO Case  °­¿õö(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 15:50~16:02 ASD: How to Perform Complicated Cases  Àº¿µ¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 16:02~16:14 PFO: Neurologist's Perspective  ±è¿µ´ë(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-13 ±×·£µåº¼·ë 16:14~16:26 PFO: Cardiologist's Perspective  ¹ÚÀçÇü(°í·ÁÀÇ´ë) 
Åä·Ð 04-13 ±×·£µåº¼·ë 16:26~16:40 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ The 2nd K-SCI Symposium : 2019-04-13""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼­¿ï¼º¸ðº´¿ø ´ëÇѽŰæµÎ°æºÎ¿µ»óÀÇÇÐȸ 2019³â KSNR Á¤±âÇмú´ëȸ ¹× ÃÑȸ 2ÀÏÂ÷ : 2019-04-13
´ÙÀ½±Û °­¸ª¾Æ»êº´¿ø ³úÁ¹Áß¼¾ÅÍ °³¼Ò 2Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2019-04-13
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
437 ¼­¿ï °Ç±¹´ëÇб³º´¿ø ´ëÇѳú½Å°æÀçÈ°ÇÐȸ 2018³âµµ ¿öÅ©¼ó : 2018-09-15 0 625 2018-08-15
436 ¼­¿ï °Ç±¹´ëÇб³º´¿ø ´ëÇѳú½Å°æÀçÈ°ÇÐȸ 2018³âµµ Ã߰迬¼ö°­Á : 2018-09-15 0 352 2018-08-15
435 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ The 17th Postgraduate Course of Diabetes : 2018-09-15 0 847 2018-08-15
434 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-15 0 888 2018-08-15
433 Á¦ÁÖ ´ëÇÑÄ¡·áÃÊÀ½ÆÄÇÐȸ Á¦4ȸ Á¤±âÇмú´ëȸ : 2018-09-14 0 964 2018-08-15
432 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 3ÀÏÂ÷ : 2018-09-14 0 2,518 2018-08-15
431 °æ³² ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ¿µ³²ÁöºÎ 2018³â 9¿ù Áý´ãȸ : 2018-09-14 0 973 2018-08-15
430 °æ±â ±¹¸³¾Ï¼¾ÅÍ 2018³â 3Â÷ ÀÇ»ý¸í°úÇÐÆ÷·³ : 2018-09-14 0 774 2018-08-15
429 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-14 0 632 2018-08-15
428 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-14 0 1,483 2018-08-15
427 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 2ÀÏÂ÷ : 2018-09-13 0 1,551 2018-08-15
426 ¼­¿ï ÀÎÁ¦´ëÇб³»ó°è¹éº´¿ø À̺ñÀÎÈÄ°ú Áý´ãȸ : 2018-09-11 0 515 2018-08-15
425 °æ±â ÇѾç´ëÇб³±¸¸®º´¿ø °©»ó¼± Á¾¾çÀÇ Áø´Ü°ú Ä¡·á: Ãֽŵ¿Çâ : 2018-09-11 0 453 2018-08-15
424 ºÎ»ê Á¦493Â÷ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2018-09-10 0 518 2018-08-15
423 ¼­¿ï °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 12ȸ °¡Å縯¼ºÇü½ÉÆ÷Áö¾ö : 2018-09-09 0 807 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷